Recurrent angioedema: Experience at a tertiary care urban medical center
Sign Up to like & getrecommendations! Published in 2021 at "Laryngoscope Investigative Otolaryngology"
DOI: 10.1002/lio2.511
Abstract: To determine the demographics, presentation, management, and outcomes of patients with recurrent angioedema. To compare the findings to patients with ACE inhibitor related angioedema. read more here.
Keywords: experience tertiary; angioedema; recurrent angioedema; tertiary care ... See more keywords
Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Immunology"
DOI: 10.1007/s10875-018-0553-4
Abstract: PurposeHereditary angioedema (HAE) is a rare disease caused by a C1 inhibitor (C1-INH) deficit. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal oedema attacks. Managing HAE patients in pregnancy is challenging,… read more here.
Keywords: inh; pregnancy; inhibitor; treatment ... See more keywords
Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study
Sign Up to like & getrecommendations! Published in 2019 at "Drug Safety"
DOI: 10.1007/s40264-019-00852-z
Abstract: IntroductionPatients taking non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban have reported experiencing angioedema in randomized trials and routine care.ObjectiveThe aim of this study was to quantify the association between NOACs… read more here.
Keywords: case crossover; warfarin; study; cohort ... See more keywords
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
Sign Up to like & getrecommendations! Published in 2022 at "The Lancet"
DOI: 10.1016/s0140-6736(21)02225-x
Abstract: BACKGROUND Hereditary angioedema is associated with dysregulation of the kallikrein-kinin system. Factor XII (FXII) is a key initiator of the kallikrein-kinin system, which produces bradykinin, a central mediator of angioedema. Garadacimab (CSL Behring) is a… read more here.
Keywords: placebo; treatment; factor xii; hereditary angioedema ... See more keywords
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2022.2105834
Abstract: ABSTRACT Introduction Hereditary angioedema due to C1-inhibitor (C1-INH-HAE) is a rare disease characterized by unpredictable swelling attacks that may be life-threatening when affecting the upper airways. Understanding the pathophysiology of HAE and the mechanism of… read more here.
Keywords: hereditary angioedema; angioedema; emerging drugs; angioedema due ... See more keywords
Risperidone induced angioedema with concurrent EPS symptoms: a case report and review of literature
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Community Hospital Internal Medicine Perspectives"
DOI: 10.1080/20009666.2018.1447215
Abstract: ABSTRACT Angioedema has recently been reported as a side effect associated with the antipsychotic risperidone. We report a case of dystonia with concurrent angioedema due to risperidone. A 40-year-old male with a history of schizophrenia… read more here.
Keywords: literature; case; report; risperidone induced ... See more keywords
Characteristics of Patients Who Underwent a Diagnostic Test for Hereditary Angioedema Admitted Due to Angioedema.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of tropical pediatrics"
DOI: 10.1093/tropej/fmac058
Abstract: OBJECTIVE Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of angioedema. This study evaluated the clinical findings and examination results of patients admitted due to angioedema who then underwent a diagnostic test for HAE.… read more here.
Keywords: hae; hereditary angioedema; angioedema; underwent diagnostic ... See more keywords
388: LIFE-THREATENING ANGIOEDEMA ASSOCIATED WITH ACEI AND SITAGLIPTIN COMBINATION THERAPY
Sign Up to like & getrecommendations! Published in 2018 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000528407.24078.64
Abstract: Critical Care Medicine • Volume 46 • Number 1 (Supplement) www.ccmjournal.org Learning Objectives: While the link between bradykinin induced angioedema and angiotensinconverting enzyme inhibitors (ACEI) is well established, less data exists on angioedema resulting from… read more here.
Keywords: medicine; sitagliptin; life threatening; dpp ... See more keywords
Hereditary angioedema
Sign Up to like & getrecommendations! Published in 2022 at "Nursing"
DOI: 10.1097/01.nurse.0000891944.11247.83
Abstract: Abstract: Hereditary angioedema is a rare and commonly misdiagnosed disease characterized by recurrent, painful, nonurticarial, and nonpruritic deep tissue swelling attacks, including potentially life-threatening asphyxiation. Nurses can assist in identifying disease hallmarks and provide emergency… read more here.
Keywords: hereditary angioedema; angioedema;
Alteplase associated Orolingual angioedema: A case report and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032474
Abstract: Objective: Orolingual angioedema (OA) is a rare but life-threatening complication of intravenous thrombolysis using alteplase. Angioedema can be caused by almost any medication. Administration of recombinant tissue plasminogen activator causes atypical angioedema. This study aimed… read more here.
Keywords: orolingual angioedema; alteplase; angioedema; case report ... See more keywords
Angioedema Risk Associated With Central Vascular Access Device Declotting
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Infusion Nursing"
DOI: 10.1097/nan.0000000000000340
Abstract: Little is known about the risk of angioedema with low-dose alteplase administration in the treatment of thrombotically occluded central vascular access devices (CVADs). To identify potential cases, the US Food and Drug Administration Adverse Event… read more here.
Keywords: central vascular; vascular access; risk; angioedema ... See more keywords